Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity.

[1]  R. Reiter,et al.  Biochemical reactivity of melatonin with reactive oxygen and nitrogen species , 2007, Cell Biochemistry and Biophysics.

[2]  P. Singal,et al.  Early changes in myocardial antioxidant enzymes in rats treated with adriamycin , 2001, Molecular and Cellular Biochemistry.

[3]  S. Grundy,et al.  Very low density lipoprotein metabolism in non-ketotic diabetes mellitus: Effect of dietary restriction , 1982, Diabetologia.

[4]  Ming‐Kuan Hu,et al.  Free radical scavenging and antioxidative activity of melatonin derivatives , 2003, The Journal of pharmacy and pharmacology.

[5]  A. Iwashita,et al.  A Novel Potent Radical Scavenger, 8-(4-Fluorophenyl)-2-((2E)-3-phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c] [1,2,4]triazine (FR210575), Prevents Neuronal Cell Death in Cultured Primary Neurons and Attenuates Brain Injury after Focal Ischemia in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  M. Zabel,et al.  Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication , 2003, Journal of pineal research.

[7]  K. Erbil,et al.  The protective effect of melatonin on adriamycin-induced acute cardiac injury. , 2003, The Canadian journal of cardiology.

[8]  C. Granier,et al.  Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[9]  J. Groves,et al.  Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction , 2003, Circulation.

[10]  R. Reiter,et al.  Oxidative Damage to Catalase Induced by Peroxyl Radicals: Functional Protection by Melatonin and Other Antioxidants , 2003, Free radical research.

[11]  A. Waśko,et al.  Synthesis and biological action of 3-R-4-substituted-delta2-1,2,4-triazoline-5-thione. , 2003, Acta poloniae pharmaceutica.

[12]  R. Reiter,et al.  Melatonin: reducing the toxicity and increasing the efficacy of drugs , 2002, The Journal of pharmacy and pharmacology.

[13]  K. Kumar,et al.  Protective effect of Gingko biloba extract against doxorubicin-induced cardiotoxicity in mice. , 2002, Indian journal of experimental biology.

[14]  C. Giulivi,et al.  Generation of Oxygen Free Radicals in Thyroid Cells and Inhibition of Thyroid Peroxidase , 2002, Experimental biology and medicine.

[15]  R. Reiter,et al.  Melatonin Protects Against Oxidative Stress Caused by δ-Aminolevulinic Acid: Implications for Cancer Reduction , 2002, Cancer investigation.

[16]  S. Nakagawa,et al.  Long‐term melatonin administration reduces hyperinsulinemia and improves the altered fatty‐acid compositions in type 2 diabetic rats via the restoration of Δ‐5 desaturase activity , 2002, Journal of pineal research.

[17]  N. Sattar,et al.  Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS) , 2001, Circulation.

[18]  I. Shimon,et al.  Serum Leptin Levels Increase following Acute Myocardial Infarction , 2001, Cardiology.

[19]  D. Acuña-Castroviejo,et al.  Free Radical‐Mediated Molecular Damage , 2001, Annals of the New York Academy of Sciences.

[20]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[21]  T. Mima,et al.  S-Allylcysteine Ameliorates Doxorubicin Toxicity in the Heart and Liver in Mice , 2000, Planta medica.

[22]  A. Matsumoto,et al.  Daily Melatonin Administration to Middle-Aged Male Rats Suppresses Body Weight, Intraabdominal Adiposity, and Plasma Leptin and Insulin Independent of Food Intake and Total Body Fat1. , 2000, Endocrinology.

[23]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[24]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[25]  Kazunori Hayashi,et al.  Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats , 1998 .

[26]  M. Tsukamoto,et al.  The antioxidant action of 2‐methyl‐6‐(p‐methoxyphenyl)‐3,7‐dihydroimidazo[1,2‐α]pyrazin‐3‐one (MCLA), a chemiluminescence probe to detect superoxide anions , 1998, FEBS letters.

[27]  H. Wong,et al.  Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFκB activation , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  D. Acuña-Castroviejo,et al.  Modification of Nitric Oxide Synthase Activity and Neuronal Response in Rat Striatum by Melatonin and Kynurenine Derivatives , 1998, Journal of neuroendocrinology.

[29]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[30]  R. Reiter,et al.  Pharmacological actions of melatonin in oxygen radical pathophysiology. , 1997, Life sciences.

[31]  P. Singal,et al.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure. , 1997, The American journal of pathology.

[32]  L. Gille,et al.  Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. , 1997, Free radical biology & medicine.

[33]  G. Warnick,et al.  Accurate direct determination of low-density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay. , 1995, Archives of pathology & laboratory medicine.

[34]  P. Jansen,et al.  Nitrite and nitrate determinations in plasma: a critical evaluation. , 1995, Clinical chemistry.

[35]  M. Dubocovich,et al.  Melatonin receptors: are there multiple subtypes? , 1995, Trends in pharmacological sciences.

[36]  S Moncada,et al.  Nitric oxide synthases in mammals. , 1994, The Biochemical journal.

[37]  C. Burtis.  Tietz textbook of Clinical Chemistry , 1994 .

[38]  D. Williams,et al.  Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice. , 1993, Cancer research.

[39]  H. Krakauer,et al.  A Method for the Quantitative Analysis and Standardization of Interleukin‐1 Bioactivity , 1991, Journal of leukocyte biology.

[40]  H. Esterbauer,et al.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.

[41]  A. Geetha,et al.  Lipids and lipoprotein profile in doxorubicin treated rats: influence of alpha-tocopherol administration. , 1990, Indian journal of experimental biology.

[42]  M. Luu,et al.  Altered thyroid hormone metabolism in advanced heart failure. , 1990, Journal of the American College of Cardiology.

[43]  C. Kurahara,et al.  Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1. , 1989, Cancer research.

[44]  N. Suttle.  Copper deficiency in ruminants; recent developments , 1986, Veterinary Record.

[45]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. , 1986, The Journal of biological chemistry.

[46]  H. Aebi,et al.  Catalase in vitro. , 1984, Methods in enzymology.

[47]  Van Vleet Jf,et al.  Effect of thyroid hormone supplementation on chronic doxorubicin (adriamycin)-induced cardiotoxicity and serum concentrations of T3 and T4 in dogs. , 1982 .

[48]  R. Brasseur,et al.  Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. , 1982, Biochemical and biophysical research communications.

[49]  M. Heiman,et al.  Inhibitory effects of a pineal extract on adrenal cortex. Lack of competition with ACTH. , 1980, Hormone research.

[50]  W. Richmond.  Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. , 1973, Clinical chemistry.

[51]  F. Sunderman.  Laboratory diagnosis of endocrine diseases , 1971 .

[52]  N. Tietz.  Fundamentals of Clinical Chemistry , 1970 .

[53]  Justus F. Mueller,et al.  The Blood Morphology of Laboratory Animals , 1968 .

[54]  W. Valentine,et al.  Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. , 1967, The Journal of laboratory and clinical medicine.

[55]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[56]  R. Havel,et al.  METABOLISM OF CONSTITUENT LIPIDS OF DOG CHYLOMICRONS. , 1963, The Journal of clinical investigation.

[57]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.